Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1010

—

4141f716-b8d2-5603-aec5-1fbc8c47dbd1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.555
  • IL6_JAK_STAT3_SIGNALING+0.474
  • MYC_TARGETS_V2+0.446
  • INFLAMMATORY_RESPONSE+0.415
  • E2F_TARGETS+0.409
  • INTERFERON_GAMMA_RESPONSE+0.409
  • G2M_CHECKPOINT+0.387
  • INTERFERON_ALPHA_RESPONSE+0.237
  • COMPLEMENT+0.187
  • TNFA_SIGNALING_VIA_NFKB+0.170

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.378
  • ESTROGEN_RESPONSE_EARLY-0.362
  • ADIPOGENESIS-0.358
  • TGF_BETA_SIGNALING-0.327
  • HEME_METABOLISM-0.320
  • ANDROGEN_RESPONSE-0.305
  • PROTEIN_SECRETION-0.295
  • UV_RESPONSE_DN-0.288
  • BILE_ACID_METABOLISM-0.259
  • CHOLESTEROL_HOMEOSTASIS-0.245

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR29022833
breast-umap@18
—D0.850
2TCGA-OL-A66I-01A-21R-A29R-07
breast-umap@18
—D0.850
3TCGA-B6-A0RT-01A-21R-A084-07
breast-umap@18
—D0.831
4C3N-02922
lung-landscapes@6
—cohortMD20.811
5TCGA-EW-A1OV-01A-11R-A144-07
breast-umap@18
—D0.806
6TCGA-90-A4EE-01A-11R-A24Z-07
lung-landscapes@6
—cohortSQ10.803
7TCGA-BH-A18V-06A-11R-A213-07
breast-umap@18
—D0.803
8C3N-01020
lung-landscapes@6
—cohortSQ10.803
9MBCProject_7544_T1_RNA
breast-umap@18
—D0.796
10SRR8518357
breast-umap@18
—D0.788

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.555Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.474Inavolisib— uncovered
MYC_TARGETS_V20.446Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.415Idelalisib— uncovered
E2F_TARGETS0.409Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.409Idelalisib— uncovered
G2M_CHECKPOINT0.387Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.237Inavolisib— uncovered
COMPLEMENT0.187Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.170Inavolisib— uncovered
PANCREAS_BETA_CELLS0.168Cobimetinib— uncovered
ANGIOGENESIS0.160Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.130Idelalisib— uncovered
KRAS_SIGNALING_UP0.128Inavolisib— uncovered
MYC_TARGETS_V10.127Inavolisib— uncovered
HEDGEHOG_SIGNALING0.125Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.094Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.057Inavolisib— uncovered
KRAS_SIGNALING_DN0.055Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.051Inavolisib— uncovered